Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.
You may also be interested in...
Fosrenol Approved In Higher Dose Formulation
FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28
Fosrenol Approved In Higher Dose Formulation
FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28
Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.